ArticleCureus2025
Understanding the Factors Related to Early Discontinuation of Lutetium-177 Vipivotide Treatment in Men With Metastatic Castration-Resistant Prostate Cancer at a Single Institution.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Lutetium-177 vipivotide tetraxetan (Lu-177 vipivotide) is a radiopharmaceutical treatment for metastatic castration-resistant prostate cancer (mCRPC). Understanding the factors that hinder treatment completion with Lu-177 vipivotide may enable clinicians to predict treatment tolerability. This retrospective review evaluates the factors associated with incomplete treatment or early discontinuation of Lu-177 vipivotide in patients with mCRPC. Methodology Patients with mCRPC who had progressed on androgen deprivation therapy and taxane chemotherapy with positive uptake on prostate-specific membrane antigen positron emission tomography imaging were treated with Lu-177 vipivotide. Initial laboratory tests included a white cell count, platelet count, hemoglobin, total bilirubin, aspartate aminotransferase, alanine aminotransferase, and creatinine. The ability to perform tasks independently was assessed using the Karnofsky Performance Scale (KPS) score. Electronic medical records were reviewed, and patients were prescribed Lu-177 vipivotide 200 mCi, administered once every six weeks, for a total of six infusions. To evaluate the original KPS, the Mann-Whitney U test was utilized. For other variables, Student's t-tests were used. Results In total, 23 patients received Lu-177 vipivotide therapy. Overall, 10 patients completed therapy, while 13 patients did not, with a median of three cycles completed. A significant difference was found between the initial mean hemoglobin for those who did not complete treatment (12.22 g/dL) and the initial mean hemoglobin for those who completed all six cycles (9.53 g/dL, p = 0.006). A significant difference was found between the median KPS score in those who completed treatment and those with early discontinuation (80 vs. 70, p = 0.005). Neither the initial platelet count (272.90 K/cumm vs. 219.15 K/cumm) (p = 0.280) nor the mean age (72.4 years vs. 75.5 years, p = 0.321) was statistically correlated with treatment completion for those who completed treatment compared to those who did not. Conclusions Low KPS score and low hemoglobin were significantly associated with those who had incomplete Lu-177 vipivotide therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.